Other

Institut National De La Sante Et De La Recherche Medicale

Institut Pasteur

Institut Pasteur De Lille

Centre National De La Recherche Scientifique

Universite De Lille II

Claude Auriault

Oleg Melnyk

François Lemonnier

Yu-Chun Lone

Anthony Pajot

Veronique Pancre

Andre Capron

Helene Gras-Masse

Jean-Olivier Durand

Denis Tranchand-Bunel

Hélène Gras-Masse

Andr&eacute; Tartar

Kader Thiam

Claudie Verwaerde

Estelle Loing

Jean Gerard Guillet

Michel Joseph

Véronique Pancre

H&eacute;l&egrave;ne Gras-Masse

Eric Diesis

Brigitte Bourez

Christophe Olivier

Ahmed Bouzidi

Jean-Michel Garcia

Xavier Duburcq

Ouafâa El-Mahdi

The present invention relates to transgenic mice and isolated transgenic mouse cells, the mice and mouse cells comprising a disrupted H2 class I gene, a disrupted H2 class II gene, a functional HLA class I transgene, and a functional HLA class II transgene. In embodiments, the transgenic mouse or mouse cells are deficient for both H2 class I and class II molecules, wherein the transgenic mouse comprises a functional HLA class I transgene and a functional HLA class II transgene. In embodiments, the transgenic mouse or mouse cell has the genotype HLA-A2HLA-DR1&#x3b2;2m&#xb0;IA&#x3b2;&#xb0;. The invention also relates to methods of using a transgenic mouse of the invention.

Transgenic mice having a human major histocompatibility complex (MHC) phenotype, experimental uses and applications

Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications

The invention concerns a reagent for diagnosing an infection caused by a virus, characterized in that it comprises essentially a mixture consisting of (1) an immunodominant fragment of a protein of said virus comprising not more than 60 aminoacids, preferably between 20 and 30 aminoacids and (2) a mixture (called mixotope) of convergent combining peptides, derived from said immunodominant fragment, which peptides are obtained by total or partial artificial degeneration of said immunodominant fragment by systematic or partial replacement of each aminoacid by another according to an appropriate substitution matrix. The invention concerns a reagent for detecting and monitoring infections caused by the Epstein-Barr virus of EBV, which is, in particular, the causal agent of infectious mononucleose and its applications for detecting an EBV infection at any stage of the infection (primo-infection, healthy carriers and induced tumors). Said diagnosis reagent comprises essentially a mixture consisting of (1) a C-terminal fragment of the protein VCAp18 SEQ ID n 1 of the Epstein-Barr virus (EBV) comprising not more than 60 aminoacids, preferably between 20 and 30 aminoacids, and (2) a mixture of convergent combining peptides, derived from said C-terminal fragment.

Reagent for detecting and monitoring viral infections

The invention concerns any lipopeptide characterized in that it comprises: a peptide part comprising the peptide sequence consisting of about 30 to about 50 of the last contiguous amino acids of the interferon-&ggr; (IFN-&ggr;) C-terminal end of mammals, whereof, if required, the last 3 to 20 amino acids have been suppressed; and one or several lipophilic parts comprising C4-C20 chain of carbon atoms, saturated or unsaturated, linear or branched, or a steroid group. The invention also concerns any lipopeptide such as defined above containing one or several CD8, and/or CD4, and/or B epitopes. The invention further concerns medicines or vaccines containing any polypeptide such as defined above.

Lipopeptides containing an interferon-&ggr; fragment, and uses thereof in pharmaceutical compositions

Novel lymphokine for suppressing platelet activation

Growing community of inventors

Juan les Pins, France

Claude Auriault